title: Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981).
abstract: From January 1, 1972 to December 31, 1981, sixty-five patients underwent pelvic exenteration as treatment for recurrent or persistent gynecologic malignancy at Memorial Sloan-Kettering Cancer Center. Cervical carcinoma was the disease most commonly treated by exenteration. The operative mortality of 9.2% represents an improvement over previous reports from this institution. After routine use of prophylactic minidose heparin, no cases of thrombophlebitis or pulmonary embolus occurred postoperatively. A 5-year survival rate of 23% warrants continued use of exenteration in carefully selected patients. The significant mortality and morbidity associated with pelvic exenteration preclude its use as a palliative procedure.
authors.affiliation: Department of Gynecology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: R A
authors.initials: RA
authors.lastname: Lawhead
authors.forename: D G
authors.initials: DG
authors.lastname: Clark
authors.forename: D H
authors.initials: DH
authors.lastname: Smith
authors.forename: V K
authors.initials: VK
authors.lastname: Pierce
authors.forename: J L
authors.initials: JL
authors.lastname: Lewis
mesh_terms: D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality / Q000601:surgery*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007412:Intestinal Fistula / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000601:surgery; D010385:Pelvic Exenteration / Q000009:adverse effects / Q000401:mortality; D012074:Remission Induction; D012189:Retrospective Studies